Sanofi's Xenpozyme gets approval in Japan for rare genetic disease

The Japanese Ministry of Health, Labor, and Welfare (MHLW) approved Sanofi's (NASDAQ:SNY) Xenpozyme (olipudase alfa) to treat adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD).